4/A: Alkermes Director Corrects Equity Award Vesting Terms

Director Shane Cooke filed an amendment to clarify the vesting schedule for previously granted stock options and restricted stock units.

Summary

• Director Shane Cooke filed an amendment to a Form 4 originally submitted on May 22, 2026.
• The amendment corrects the reported vesting terms for 11,538 non-qualified stock options and 5,409 restricted stock units granted on May 20, 2026.
• The corrected vesting schedule stipulates that awards vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual general meeting occurring at least 50 weeks after the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event with no impact on the company's operational or financial trajectory.

Positives

• Transparency in correcting administrative reporting errors regarding director compensation.

Negatives

• Initial administrative error in reporting the vesting terms of director equity awards.

Risks

• None identified; this is a routine administrative correction.

Future Outlook

The filing does not provide forward-looking business guidance, focusing solely on the correction of director equity award terms.

Industry Context

StockSavvy.ai notes that administrative amendments to Form 4 filings are common in the pharmaceutical and biotech sectors, where director compensation packages often involve complex vesting schedules tied to annual general meetings.

Comparison to Industry Standards

• The vesting terms described are consistent with standard corporate governance practices for non-executive directors in the biopharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; the filing ensures accurate reporting of director equity holdings.

Next Steps

• No further actions required by the issuer regarding this specific filing.

Key Dates

Keywords

Alkermes, ALKS, Director Compensation, Form 4/A, Equity Vesting, Shane Cooke